| SST |
| LOCUS ID | 6750 | |||||||||||||
| GENE_SYMBOL | SST | |||||||||||||
| GENE NAME | somatostatin | |||||||||||||
| SYNONYMNS | SMST | |||||||||||||
| CHROMOSOME | 3 | |||||||||||||
| HOMOLOGENE ID | 819 |
| microRNAs | NA | NA |
| GENE SUMMARY |
|---|
| The hormone somatostatin has active 14 aa and 28 aa forms that are produced by alternate cleavage of the single preproprotein encoded by this gene. Somatostatin is expressed throughout the body and inhibits the release of numerous secondary hormones by binding to high-affinity G-protein-coupled somatostatin receptors. This hormone is an important regulator of the endocrine system through its interactions with pituitary growth hormone, thyroid stimulating hormone, and most hormones of the gastroi |
| OBSERVATIONS |
|---|
| Complication | Evidence | PMID |
| Nephropathy | 1. The growth hormone (GH)-insulin-like growth factor (IGF)-SST (SST) axis is involved in diabetic nephropathy (DN). We have recently shown a beneficial effect on diabetic kidney disease markers by the use of a novel somatostatin (SST) analogue (PTR-3173) (S) | 15494355 |
| Retinopathy | 1. Potential therapeutic uses for somatostatin analogues include diabetic complications like retinopathy, nephropathy and obesity, due to inhibition of IGF-1, VEGF together with insulin secretion and effects upon the renin-angiotensin-aldosterone system. | 25956467 |